Jiangsu Vcare——Innovative Drugs R&D Business

As the parent company, Jiangsu Vcare is at the forefront of innovative drug R&D. With a clear mission to address unmet clinical needs, such as "overcoming resistance," "resolving drug resistance," and "enhancing target selectivity." The company has established a pipeline centered on Vicagrel, with five clinical-stage Class I innovative drugs under development. VC004 capsules: an oral targeted anti-tumor drug; Vicagrel capsules: an oral anti-thrombotic agent;  VC005 tablets: an oral immunomodulatory and anti-inflammatory drug; VC005 gel: a topical immunomodulatory and anti-inflammatory agent. Additionally, multiple preclinical projects are ongoing, targeting indications in cardiovascular, oncology, autoimmune, and inflammatory diseases, aiming to expand into global markets.

Nanjing Vcare——Comprehensive Drug Industry Chain Services

Nanjing Vcare, a wholly-owned subsidiary of Jiangsu Vcare, provides comprehensive, end-to-end services across the entire pharmaceutical value chain. With a global outlook and commitment to excellence. , Nanjing Vcare supports R&D and production of chemical drugs throughout their full lifecycle. Nanjing Vcare offers a comprehensive "Chemistry + Pharmacy + Medicine" one-stop CRO/CDMO service platform, providing services that ranging from advanced pharmaceutical intermediates to APIs under CDMO agreements, and CRO technical support from preclinical to clinical stages. Its R&D capabilities are enhanced by advanced platforms, including synthetic biology. For production, it operates "Hubei Tianshu Pharmaceutical Co., Ltd.", a facility specializing in intermediates and APIs, ensuring full-chain support for both clients and the parent company’s commercial-scale production.

Company Scale

R&D Headquarters: Located in the Jiangbei New District High-Tech Biopharmaceutical Valley (Nanjing), with a 20,000+㎡ R&D center housing laboratories for synthesis, formulation, analysis, crystallography, cell culture, and SPF-grade animal facilities. Advanced platforms include: AIDD molecular generation, drug screening, synthetic biology, continuous flow engineering, photochemistry, chiral drug synthesis & analysis, polymorph/salt screening, complex drug formulation technologies. Production Base: situated in the Hubei Xiangyang (Yicheng) Fine Chemical Industrial Park, covering 130 acres with. It has two API production lines and nine intermediate production lines; the total production capacity reaches 255 m³, equipped with 100+ multifunctional reactors; compliance with international quality management systems. Workforce: over 900 employees, including 16 Ph.D. holders, nearly 200 master’s degree holders, and technical staff comprising 84% of the workforce, forming a highly skilled R&D and production team.

Financing & Honors

Jiangsu Vcare initiated its Series A financing in 2021 and has since successfully closed multiple funding rounds (A/A1/A2/B/C/C+). As of January 2025, the total funding raised exceeds RMB 1 billion. Its differentiated advantages in innovative drug development and unique dual-pillar business model continue to garner sustained strong recognition from capital markets. Recognized as a “National-Level Specialized, Refined, Differential, and Innovative ‘Little Giant’ Enterprise” (2024). Other key accolades include: Jiangsu Provincial Engineering Technology Research Center for Chemical Innovative Drugs; Jiangsu Provincial Enterprise Academician Workstation; Nanjing Postdoctoral Innovation Practice Base; China Pharmaceutical University Enterprise Graduate Workstation; Nanjing Cultivated Unicorn Enterprise and Innovative Leader Enterprise, etc.

Future Vision

Guided by the founding principle “The Better Care, The Better Medicines,” Jiangsu Vcare remains committed to advancing healthcare through purposeful innovation.We will continue synergizing our dual business segments—innovative drug development and full-spectrum industry services—to incubate more Class I innovative drugs that address critical clinical needs through differentiated strategies.With a clear focus on science and service, we are driven by a shared vision:“Innovation for a Healthier Future.”